Recent Quotes
View Full List
My Watchlist
Champion Real Estate Investment Trust
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
DataMeds AI, Inc. - Common Stock
(NQ:
MEDS
)
1.340
+0.612 (+84.14%)
Official Closing Price
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about DataMeds AI, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Postmarket movers: WETO and GOVX lead after-hours gainers as SHFS and TOVX slip
↗
November 20, 2026
Via
Chartmill
Today's Top Stock Movers: MSS Surges 97.0%, VWAV Plunges 71.02%
↗
November 20, 2026
Via
Chartmill
Top Movers in Today's US Session: SLDPW and MSS Lead Gainers; VWAV and BBA.W Lead Losers
↗
November 20, 2026
Via
Chartmill
AI-Powered Cancer Blood Tests Set the Stage for a Multibillion-Dollar Biotech Breakthrough
November 20, 2026
Emerging Technologies Target Earlier Detection of Breast and Colon Cancer as Global Demand for Advanced Diagnostics Accelerates
From
FN Media
Via
GlobeNewswire
AI-Powered Cancer Blood Tests Set the Stage for a Multibillion-Dollar Biotech Breakthrough
November 20, 2026
EQNX::TICKER_START (NASDAQ:MEDS),(NASDAQ:GH),(NASDAQ:GRAL),(NASDAQ:NTRA),(NASDAQ:FRNM) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Premarket Movers on Nov. 20, 2026: Gainers and Losers
↗
November 20, 2026
Via
Chartmill
Postmarket Movers: Nov. 19 After-Hours Gainers and Losers
↗
November 19, 2026
Via
Chartmill
DataMEDS AI Agrees to Acquire TBIA Cancer AI Blood Test Platform From Todos Medical Estate for Subsidiary Helomics, Inc.
November 19, 2026
CLIA-Certified Cancer Diagnostics Laboratory Will Acquire Spectroscopy Platform to Support Machine Learning Expansion into Additional Cancer Types CE Marks previously held in Europe for breast cancer...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
How AI and Anticancer Peptides Could Reshape the Future of Cancer Treatment
November 18, 2026
EQNX::TICKER_START (NASDAQ:MEDS),(NASDAQ:NEO),(NASDAQ:ANT),(NASDAQ:RXRX),(NASDAQ:OBIO) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
How AI and Anticancer Peptides Could Reshape the Future of Cancer Treatment
November 18, 2026
Advanced AI Platforms Are Helping Researchers Identify New Cancer Targets, Engineer Promising Peptides, and Accelerate Next-Generation Drug Development
From
FN Media
Via
GlobeNewswire
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
November 18, 2026
Cooperation Between CLIA-Certified Cancer Diagnostics Laboratory and Canadian Tech-Bio Company Will Allow Artificial Intelligence Models to Interrogate World's Largest Primary Tumor Biobank DiaGen...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
UPDATING ORIGINAL RELEASE DataMEDS AI Releases CEO Letter
November 16, 2026
Interim Co-CEO Lays Out Strategy Across Recent Investments Focused on the Synergies in the Company's Emerging Healthcare Ecosystem Ongoing turnaround focused on financial discipline, strategic...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Releases CEO Letter
November 16, 2026
Interim Co-CEO Lays Out Strategy Across Recent Investments Focused on the Synergies to in the Company's Emerging Healthcare Ecosystem Ongoing turnaround focused on financial discipline, strategic...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
November 13, 2026
Third quarter 2026 revenue of $2.7 million, up 50% from $1.8 million in the second quarter of 2026, primarily driven by growth in Corexa Pharmacy drug dispensing Launch of the Health Lives Here mobile...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Announces Corexa Pharmacy's First Commercial Sale of Compounded Peptides Under FDA Enforcement Discretion Policy
November 09, 2026
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
November 05, 2026
NFL Alumni Health to support HMO member engagement Relationship centers on improving member GLP-1 related outcomes through use of the Health Lives Here app and easy access to telehealth, pharmacy and...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
November 03, 2026
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
November 02, 2026
Corexa Pharmacy to dispense compounded BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax in accordance with HHS' recently updated Enforcement Discretion Policy Bulk drug substance access facilitates 3PL...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
October 23, 2026
Being marketed to 6,500+ Corexa Health Pharmacy Network of independent pharmacies To be launched first at Corexa Pharmacy in Lakeland, FL retail location in Q4/2026 Program will aim to bring best...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DefenseNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT)Signs Letter of Intent to Acquire 19.9% Stake in DataMEDS AI (NASDAQ: MEDS)
October 22, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
October 22, 2026
Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion in 2025 to $93.4 billion in 2035 Customer Acquisition Plan...
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMeds Regains Compliance With NASDAQ Listing Standards
October 20, 2026
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
Premarket Movers Oct. 19: Disc Medicine Jumps 51.62%, Rubico Falls 33.84%
↗
October 19, 2026
Via
Chartmill
DataMeds Applauds FDA’s Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health’s Peptides Roadmap
October 16, 2026
DataMeds AI, Inc. (NASDAQ:MEDS) today applauded the issuance of a new policy proposal by the U.S. Food and Drug Administration (FDA) entitled “Interim Access Policy for Compounding Using Certain...
Via
B2i Digital
Topics
Artificial Intelligence
DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
October 16, 2026
Corexa Health's three divisions - pharmacy, distribution, and tech & hub - positioned to serve the emerging compounded peptide market
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS Si Licenses U.S. Rights To Reboot Health AI’s Direct-To-Consumer GLP-1 Weight Management Platform
October 14, 2026
DataMeds AI, Inc. (NASDAQ:MEDS) today announced that it has entered into an exclusive license, revenue sharing and marketing agreement with REBOOT Health AI, Inc. (“REBOOT”) for Direct-to-Consumer...
Via
B2i Digital
Topics
Artificial Intelligence
Intellectual Property
DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
October 14, 2026
Platform to be integrated into Health Lives Here app as a subscription offering
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
October 13, 2026
DataMeds AI, Inc. (NASDAQ:MEDS) today announced that it has implemented cost control measures, primarily through reductions in corporate management positions, to focus the workforce spend on...
Via
B2i Digital
Topics
Artificial Intelligence
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
October 13, 2026
Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx ® Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers
From
DataMEDS AI, Inc.
Via
ACCESS Newswire
DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx® Assay In Gynecologic Cancers
October 12, 2026
DataMeds AI, Inc. (NASDAQ:MEDS) today announced that its recently acquired CLIA-certified precision oncology laboratory subsidiary Helomics Corporation has received a Medicaid coverage determination in...
Via
B2i Digital
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.